Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hypertension
Volume 2014 (2014), Article ID 835716, 10 pages
http://dx.doi.org/10.1155/2014/835716
Review Article

Lifestyle Factors in Hypertension Drug Research: Systematic Analysis of Articles in a Leading Cochrane Report

1Allan McGavin Sports Medicine Centre, University of British Columbia, Vancouver, BC, Canada V6T 1Z3
2Father David Bauer Clinic (Centric Health Corporation), Calgary, AB, Canada T2N 3Y9
3CBI Health Centre, Duncan, BC, Canada V9L 1N8
4Squamish Physio & Wellness Centre, Squamish, BC, Canada V8B 0B4
5Movéo Sport and Rehabilitation Centre, North Vancouver, BC, Canada V7L 2P7
6Department of Physical Therapy, Faculty of Medicine, University of BC, Vancouver, BC, Canada V6T 1Z3

Received 12 August 2013; Revised 12 November 2013; Accepted 26 November 2013; Published 28 January 2014

Academic Editor: Kazuomi Kario

Copyright © 2014 Dan E. Wilson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. Musini, “Evidence for practice: bringing best hypertension evidence to front line: first line treatments and second line treatments,” Cochrane Hypertension Group, 2012, http://hypertension.cochrane.org/evidence-practice.
  2. S. S. Daskalopoulou, N. A. Khan, R. R. Quinn et al., “The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy,” Canadian Journal of Cardiology, vol. 28, no. 3, pp. 270–287, 2012. View at Publisher · View at Google Scholar
  3. Q. Bui, “First-line treatment for hypertension,” American Family Physician, vol. 81, no. 11, pp. 1333–1335, 2010. View at Google Scholar · View at Scopus
  4. A. V. Chobanian, G. L. Bakris, H. R. Black et al., “Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure,” Hypertension, vol. 42, no. 6, pp. 1206–1252, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. P. K. Whelton, J. He, L. J. Appel et al., “Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program,” Journal of the American Medical Association, vol. 288, no. 15, pp. 1882–1888, 2002. View at Google Scholar · View at Scopus
  6. A. J. J. Wood, “Drug interactions in hypertension,” Hypertension, vol. 11, 3, supplement 2, pp. S1–S3, 1988. View at Google Scholar · View at Scopus
  7. L. J. Appel, L. S. Cooper, E. Obarzanek et al., “Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial,” Journal of the American Medical Association, vol. 289, no. 16, pp. 2083–2093, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. J. M. Wright and V. M. Musini, “First-line drugs for hypertension,” Cochrane Database of Systematic Reviews, no. 3, Article ID CD001841, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. A. B. Carter, “Hypotensive therapy in stroke survivors,” The Lancet, vol. 1, no. 7645, pp. 485–489, 1970. View at Google Scholar · View at Scopus
  10. “Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party,” British Medical Journal, vol. 304, no. 6824, pp. 405–412, 1992. View at Scopus
  11. “MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party,” British Medical Journal, vol. 291, no. 6488, pp. 97–104, 1985. View at Scopus
  12. P. Leren and A. Helgeland, “Oslo hypertension study,” Drugs, vol. 31, supplement 1, pp. S41–S45, 1986. View at Google Scholar · View at Scopus
  13. A. Helgeland, “Treatment of mild hypertension: a five year controlled drug trial. The Oslo study,” American Journal of Medicine, vol. 69, no. 5, pp. 725–732, 1980. View at Google Scholar · View at Scopus
  14. J. L. Probstfield, “Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP),” Journal of the American Medical Association, vol. 265, no. 24, pp. 3255–3264, 1991. View at Publisher · View at Google Scholar · View at Scopus
  15. N. O. Borhani, W. B. Applegate, J. A. Cutler et al., “Part 1: rationale and design,” Hypertension, vol. 17, supplement 3, pp. S2–S15, 1991. View at Google Scholar · View at Scopus
  16. H. M. Perry Jr., W. McFate Smith, R. H. McDonald et al., “Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study,” Stroke, vol. 20, no. 1, pp. 4–13, 1989. View at Google Scholar · View at Scopus
  17. W. B. Kannel, P. A. Wolf, J. Verter, and P. M. McNamara, “Epidemiologic assessment of the role of blood pressure in stroke. The Framingham study,” Journal of the American Medical Association, vol. 214, no. 2, pp. 301–310, 1970. View at Publisher · View at Google Scholar · View at Scopus
  18. T. M. Vogt, C. C. Ireland, and D. Black, “Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study,” Controlled Clinical Trials, vol. 7, no. 2, pp. 118–133, 1986. View at Google Scholar · View at Scopus
  19. W. McFate Smith, “Isolated systolic hypertension in the elderly,” Current Medical Research and Opinion, vol. 8, supplement 1, pp. S19–S29, 1982. View at Google Scholar · View at Scopus
  20. R. Reader, G. E. Bauer, and A. E. Doyle, “The Australian therapeutic trial in mild hypertension. Report by the management committee,” The Lancet, vol. 1, no. 8181, pp. 1261–1267, 1980. View at Google Scholar · View at Scopus
  21. A. Amery, W. Birkenhager, C. J. Bulpitt et al., “Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol, and organization,” Aging, vol. 3, no. 3, pp. 287–302, 1991. View at Google Scholar · View at Scopus
  22. S. Eriksson, B. Olofsson, and P. Wester, “Atenolol for secondary prevention after stroke,” Cerebrovascular Diseases, vol. 5, no. 1, pp. 21–25, 1995. View at Google Scholar
  23. “UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance,” Diabetologia, vol. 34, no. 12, pp. 877–890, 1991. View at Scopus
  24. “Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group,” British Medical Journal, vol. 317, no. 7160, pp. 713–720, 1998. View at Scopus
  25. W. M. Smith, “Treatment of mild hypertension: results of a ten-year intervention trial,” Circulation Research, vol. 40, no. 5, supplement 1, pp. S98–105, 1977. View at Google Scholar
  26. Veterans Administration Cooperative Study Group on Antihypertensive Agents, “Effects of treatment on morbidity in hypertension. II: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg,” Journal of the American Medical Association, vol. 213, no. 7, pp. 1143–1152, 1970. View at Google Scholar
  27. “Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility trial: plan and preliminary results of a two-year feasibility trial for a multicenter intervention study to evaluate the benefits versus the disadvantages of treating mild hypertension: prepared for the Veterans Administration-National Heart, Lung, and Blood Institute Study Group for evaluating treatment in mild hypertension,” Annals of the New York Academy of Sciences, vol. 304, pp. 267–288, 1978.
  28. The Cochrane Collaboration, 2012, http://www.cochrane.org.
  29. B. Aertgeerts and F. Cools, “The Cochrane Collaboration and systematic literature reviews about the efficiency of a treatment,” Verhandelingen, vol. 69, no. 5-6, pp. 335–350, 2007. View at Google Scholar · View at Scopus
  30. A. M. Moseley, M. R. Elkins, R. D. Herbert, C. G. Maher, and C. Sherrington, “Cochrane reviews used more rigorous methods than non-Cochrane reviews: survey of systematic reviews in physiotherapy,” Journal of Clinical Epidemiology, vol. 62, no. 10, pp. 1021–1030, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. A. W. Jørgensen, J. Hilden, and P. C. Gøtzsche, “Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review,” British Medical Journal, vol. 333, no. 7572, pp. 782–785, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. Hypertension Canada, “2012 CHEP recommendations for management of hypertension,” 2012, http://www.hypertension.ca/images/2012_CHEPFullRecommendations_EN_HCP1009.pdf.